Posters
“Cytochrome BD Oxidase in Mycobacterium tuberculosis – A Journey to Find Novel Inhibitor Scaffolds.” Kate Marshall, Bei Shi Lee, Nitin P. Kalia, Carrie Frey, William Claypool, Rui Liu, Marvin J. Miller, Kevin Pethe, and Garrett C. Moraski, Mycobacteria 2026: Translating Biology into Cures, NTU Singapore, May 25-26, 2026.
“Next Generation Imidazo[1,2-a]pyridine-3-carboxamides.” Garrett C. Moraski, Kate Marshall, Jeffery S. Schorey, Kyung Bae Choi, Gauri Shetye, Scott G. Franzblau, Carry Frey, Ivan Joseph, Wiilliam Claypool, Marvin J. Miller, 2025 Tuberculosis Drug Discovery and Development GRC, Barcelona, 2025, Spain, July 20-25.
“Effects of deuteration on the metabolism of Imidazo[1,2-a]pyridine-3-carboxamides for the treatment of tuberculosis.” Rui Lui, Kate Marshall, Rui Ma, Kim Lien Thi Pham, Guri Shetye, Zhihao Liu, Sanghyun Cho, Hyuhyoung Jeong, Scott G. Franzblau, Garrett C. Moraski, Marvin J. Miller, Poster 30, 2018 Northwest Regional Meeting (NORM), Bozeman, MT, June 28-30.
“ND-11176, a Potential Clinical Candidate for the Treatment of Mycobacterium abscessus Infection in Cystic Fibrosis Patients.” Yong Cheng, Xuejuan Tan, Emily A. Cronberger, Garrett C. Moraski, Marvin J. Miller and Jeffrey S. Schorey, Poster NO. AAR738, ASM Microbe 2019, San Diego, CA, June 21, 2019.
“A Small-molecule inhibitor of the cytoxhrome bd oxidase for tuberculosis.” Bei Shi Lee, Nitin P. Kalia, Marvin J. Miller, Garrett C. Moraski and Kevin Pethe. 2019 Keystone Meeting, Tuberculosis: Mechanisms, Pathogenesis and Treatment (A3), Banff, Alberta Canada, January 17—21, 2019.
“ND-11543: A potent anti-mycobacterial Imidazo[2,1-b]thiazole-5-carboxamide agent.” Garrett C. Moraski, Yong Cheng, Matthew Zimmerman, Gauri Shetye, Sanghyun Cho, Scott G. Franzblau, Jeffery S. Schorey, Marvin J. Miller, 2018 Northwest Regional Meeting (NORM), Richland, WA, June 24-27.
“Imidazo[1,2-a]pyridine-3-carboxyamides: A “Dual Threat” Against Mycobacterium tuberculosis and Mycobacterium avium.” Garrett C. Moraski, Yong Cheng, Jeffery S. Schorey, Sanghyun Cho, Scott G. Franzblau, Marvin J. Miller, 30th Annual Fall ACS Meeting, Anaconda, MT October 6-8, 2017.
“Fire without Flint: Cofactorless strategies for converting biopolymers into useful chemical precursors.” Jennifer DuBois, Garrett Moraski, Gregg Beckham, 254th ACS National Meeting & Exposition, Washington, D.C., August 20–24, 2017.
“Design, Syntheses and Studies of New Potent and Selective Anti-tuberculosis Agents Based on Imidazopyridine and Imidazothiazole Cores.” Garrett Moraski, Marvin Miller, Jeffrey Schorey, Yong Cheng, Michael Goodwin, Matthew Zimmerman, Helena Boshoff, Sanghyun Cho, Surafel Mulugeta, Jeffery Anderson, Scott Franzblau, EMBO Tuberculosis Meeting, Paris, FR, September 23, 2016.
“HT-03- A Novel Anti-mycobacterial Imidazo[2,1-b]thiazole-5-carboxamide – Demonstrates Favorable Safety and Pharmacokinetics.” Garrett C. Moraski, Yong Cheng, Michael Goodwin, Matthew Zimmerman, Helena I. Boshoff, Sanghyun Cho, Jeffery R. Anderson, Surafel G. Mulugeta, Scott G. Franzblau, Jeffrey S. Schorey, Marvin J. Miller, ASM Microbe 2016, Boston, MA, June 19, 2016.
“Arrival of Imidazo[2,1-b]thiazole-5-carboxamides as Potent Inhibitors of Mycobacterium tuberculosis.” Garrett C. Moraski, Helena Boshoff, Patricia Miller, Sanghyun Cho, Scott G. Franzblau, Marvin J. Miller, New Antibacterial Agents (#236), Pacifichem, Honolulu, HI, December 16, 2015.
“Imidazo[1,2-a]pyridine-3-carboxyamides are a “Dual Threat” Against Mycobacterium tuberculosis and Mycobacterium avium at Nanomolar Concentrations.” Garrett C. Moraski; Yong Cheng, Jeffery S. Schorey, Scott G. Franzblau, Marvin J. Miller, F-287, ICAAC/ICC 2015, San Diego, CA, September 17-21.
“Putting TB to rest: Ambien® “Anangrams” Affording Antitubercular Activity.” Garrett C. Moraski, Patricia Miller, Marvin J. Miller, Sanhyun Cho, Jeffery Anderson, Surafel Mulugeta, Scott G. Franzblau, Helena Boshoff, 2014 Northwest American Chemical Society Regional Meeting, Missoula, MT, June 22 – 25, 2014.
“Driving discovery of new antituberculosis agents.” Marvin J. Miller, Garrett Moraski, Scott Franzblau, Philip Hipskind, Thierry Masquelin, Alexander Godfrey, Tanya Parish, 246th ACS National Meeting & Exposition, Indianapolis, IN, September 8-12, 2013.
“Synthesis of an imidazopyridine library using the Automated Synthesis/purification Laboratory (ASPL).” Marvin J. Miller, Jeffrey Schorey, Garrett C. Moraski, Scott G. Franzblau, Philip A. Hipskind, Thierry J. Masquelin, Alexander G. Godfrey, Jeffrey Cramer, Tanya Parish, 246th ACS National Meeting & Exposition, Indianapolis, IN, September 8-12, 2013.
“Mechanism of Action of the Imidazo[1,2-a]pyridine-3-carboxamides against Mycobacterium tuberculosis.” J. V. Early, T. O’Malley, G. C. Moraski, M. J. Miller, T. Masquelin, T. Ioerger, J. Sacchettini, P. Hipskind, T. Parish, ICAAC, Denver, CO, September 9-13, 2013.
“Synthesis and Evaluation of Antiproliferative N-((1-Benzyl-1H-1,2,3-triazol-4- yl)methyl)arylamides.” Garrett C. Moraski, Manuka Ghosh, Jonathan A. Stefely, Rahul Palchaudhuri, Patricia A. Miller, Rebecca J. Peterson, Paul J. Hergenrother, and Marvin J. Miller, Eli Lilly & Company, Indianapolis, IN, November 30, 2011.
“Syntheses and evaluation of new anti-tuberculosis agents inspired by studies of mycobacterial iron assimilation processes.” Marvin J. Miller, Garrett C. Moraski, Helen Zhu, Andrew J. Walz, Jingdan Hu, Yanping Xu, Chunrui Wu, Lowell Markley, Patricia Miller, Scott Franzblau, Ute Moellmann, and Helena Boshoff, Tuberculosis Drug Development Gordon Conference, Il Ciocco Hotel and Resort, Lucca (Barga), Italy, July 3- 8, 2011.
“Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.” Garrett C. Moraski, Lowell D. Markley , Philip A. Hipskind, Helena Boshoff, Sanghyun Cho, Scott G. Franzblau and Marvin J. Miller, CBBI annual retreat, Notre Dame, IN, May 16, 2011.
“Allylic thiocyanates and isothiouronium salts as new antituberculosis agents.” Silveira, G. P.; Ferreira, M.; Fernandes, L.; Moraski, G. C.; Miller, M. J.; Sá, M. M., 5th Brazilian Symposium on Medicinal Chemistry – BrazMedChem2010, Arts and Convention Center of Federal University of Ouro Preto, Brazil, November 6 – 9, 2010.
“Discovery of ND-008454: A Potent MDR and XDR Antituberculosis Agent.” Garrett Moraski, Lowell Markley, Mayland Chang, Helena Boshoff, Scott Franzblau, Phillip Hipskind and Marvin Miller, CBBI annual retreat, Notre Dame, IN, May 17, 2010.
“Design, Syntheses and Studies of Mycobacterial Siderophores, Analogs, Components and Drug Conjugates with Selective Anti-tuberculosis Activity.” Marvin J. Miller, Garrett C. Moraski, Helen Zhu, Andrew J. Walz, Jingdan Hu, Yanping Xu, Chunrui Wu, Scott Franzblau, Ute Moellmann, Gordon Conference, Oxford, England, August 16-21, 2009.
“Evaluation of Oxazoline and Oxazole Anti-Tuberculosis Agents.” Garrett C. Moraski, Marvin J. Miller, Scott Franzblau, Ute Moellmann, Miller Symposium, Notre Dame, IN, October 25, 2008.
“Synthesis and Biological Evaluation of Novel Heterocyclic anti-Tuberculosis Agents from Spartan Oxazoline and Oxazole Benzyl Esters.” Garrett C. Moraski, Marvin J. Miller, Scott Franzblau and Ute Mollmann, CBBI annual retreat, Granger, IN, May 17, 2007.
“Design, Syntheses and Studies of Novel Anti-TB Agents and Siderophores.” Marvin J. Miller, Garrett C. Moraski, Helen Zhu, Scott Franzblau, Ute Moellmann, 6th International Biometals Symposium, Santiago de Compostela, Spain, July 14-18, 2008.
“Mycobactin Fragment Analogs as Potential Small-Molecule TB Growth Inhibitors: Discovery of a Novel Method for Imidazole Synthesis.” B. S. Bodnar, G. C. Moraski,, M. J. Miller, National Organic Symposium, Chapel Hill, NC, June 3 – 8, 2007.
“Synthesis and Biological Evaluation of Novel Heterocyclic Anti-tuberculosis Agents from Spartan Oxazoline and Oxazole Benzyl Esters.” Garrett C. Moraski, Marvin J. Miller, Scott Franzblau and Ute Mollmann, CBBI annual retreat, Granger, IN, May 17, 2007.
“Design, Syntheses and Studies of Novel Anti-TB Agents Based on Mycobacterial Siderophores.” M. J. Miller, Y. Xu, H. Zhu, K. A. Fennell, B. Bodnar, G. Moraski, S. Franzblau, U. Moellmann, Gordon Conference, Ventura, California, 2006.
“Design, Synthesis, and Studies of Mycobacterial Siderophores with Selective Anti-TB Activity.” M. J. Miller, J. Hu, Y. Xu, A. J. Walz, H. Zhu, K. A. Fennell, B. Bodnar, G. Moraski, S. Franzblau, U. Moellmann, Keystone Meeting, Montreal, CA, 2006.
“Probing the Structural Basis for Anti-Tuberculosis and Anti-Cancer Activity in Amamistatin and Mycobacteria Analogs.” B. S. Bodnar, M. J. Miller, G. C. Moraski, National Organic Symposium, Salt Lake City, UT, June 13-16, 2005.
“Probing the Structural Basis for Anti-Tuberculosis and Anti-Cancer Activity in Amamistatin and Mycobactin Analogs.” B. S. Bodnar, M. J. Miller, K. A. Fennell, G. C. Moraski, H. Zhu. National Organic Symposium, Salt Lake City, UT, June 13-16, 2005.
“Design, Syntheses and Studies of Mycobacterial Siderophores with Selective antiTB Activity.” M. J. Miller, J. Hu, Y. Xu, A. J. Walz, H. Zhu, K. A. Fennell, B. Bodnar, A. Sheinkman, G. Moraski, S. Franzblau, U. Moellmann, Tuberculosis: Integrating Host and Pathogen Biology (D1), Whistler, Canada, April 2-7, 2005.
“Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitors.” Garrett Moraski, Joseph Lyssikatos, Pfizer Cancer Symposium Poster Session, Groton, CT, 2000.
“Synthesis of a Farnesyl Transferase Inhibitor Drug Candidate.” Garrett Moraski, Joseph Lyssikatos, Pfizer Central Research Cancer Poster Session, Groton, CT, 1998.
“Stereospcific Cyclopropanes from Homo-propargylic Alcohols.” Garrett Moraski, Richard Taylor, Undergraduate Poster Day, University of Notre Dame, Notre Dame IN, 1996.